You are here

Article Text

Article menu
Download PDFPDF
Concise report
Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis
  1. Marloes W Heijstek1,
  2. Gecilmara C S Pileggi1,2,
  3. Evelien Zonneveld-Huijssoon1,
  4. Wineke Armbrust3,
  5. Esther P A H Hoppenreijs4,
  6. Cuno S P M Uiterwaal5,
  7. Wietse Kuis1,
  8. Nico M Wulffraat1
  1. 1
    Department of Paediatric Immunology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, PO Box 85090, 3508 AB Utrecht, The Netherlands
  2. 2
    Department of Paediatric Rheumatology and immunology, School of Medicine of Ribeirão Preto, University of Sao Paulo, Brasil
  3. 3
    Department of Paediatric Rheumatolgy, Beatrix Children’s Hospital, University Medical Centre Groningen, The Netherlands
  4. 4
    Department of Paediatrics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  5. 5
    Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, The Netherlands
  1. N M Wulffraat, Department of Paediatric Immunology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Room KC 03-0630, PO Box 85090, 3508 AB Utrecht, The Netherlands; n.wulffraat{at}umcutrecht.nl

Abstract

Objective: To assess the effect of measles, mumps and rubella (MMR) vaccination on disease activity in children with juvenile idiopathic arthritis (JIA).

Methods: A retrospective observational multicentre cohort study was performed in 314 patients with JIA, born between 1989 and 1996. Disease activity and medication use were compared during the period of 6 months before vaccination versus 6 months after vaccination. Disease activity was measured by joint counts, the Physician’s global assessment scale and erythrocyte sedimentation rate. Next, we compared disease activity in patients vaccinated between 8 and 9 years of age with the activity in patients who had not been vaccinated at this time (who received MMR between the ages of 9 and 10 years).

Results: No increase in disease activity or medication use was seen in the 6 months after MMR vaccination (n = 207), including in patients using methotrexate (n = 49). No overt measles infections were noted. When disease activity in vaccinated patients (n = 108) was compared with activity in those not yet vaccinated (n = 86), there were no significant differences.

Conclusions: The MMR booster vaccination does not seem to aggravate disease activity in JIA. This indicates that the most patients with JIA can be vaccinated safely with the MMR vaccine. A prospective study is recommended.

  • measles
  • mumps and rubella vaccination
  • juvenile idiopathic arthritis
  • methotrexate
  • disease activity parameters
  • flares

https://doi.org/10.1136/ard.2006.063586

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None declared.

    • Abbreviations:
      CHAQ
      Childhood Health Assessment Questionnaire
      DMARD
      disease-modifying anti-rheumatic drug
      ESR
      erythrocyte sedimentation rate
      ILAR
      International League of Associations for Rheumatology
      JIA
      juvenile idiopathic arthritis
      MMR
      measles, mumps and rubella
      NSAID
      non-steroidal anti-inflammatory drug
      PGA
      physician’s global assessment
      RF
      rheumatoid factor